Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

Beyfortus, the new monoclonal antibody injection, similarly reduces the risk of RSV in infants for about five months—or one RSV season. In adults, the most frequently reported side effects have ...

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

A monoclonal antibody -- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective ...

long-acting monoclonal antibody for the prevention of RSV in infants. Previously, palivizumab was the only preventative option and required monthly injections to sustain its protective effect.

Dr Reddy’s & Sanofi Healthcare expand partnership to unveil Beyfortus, a novel drug to prevent RSV in India: Our Bureau, Bengaluru Tuesday, April 29, 2025, 12:15 Hrs [IST] Dr Re ...

The Vermont pandemic death total stands at 1,289 as of April 19, 2025, with 1 reported death from the previous week (the most ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.

“That’s showing a significant reduction in RSV being diagnosed in pediatric patients who received the monoclonal antibody, which was very interesting to us because it’s showing the ...

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...